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At Risk for Huntington's Disease
HD is a genetically caused brain disorder that causes uncontrollable bodily movements and robs
people's ability to walk, talk, eat, and think. The final result is a slow, ugly death. Children of parents
with HD have a 50-50 chance of inheriting the disease. There is no cure or treatment.
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Moving toward a potential treatment: Isis, CHDI
researchers outline upcoming Huntington’s disease
gene-silencing trial
Scientific research and clinical trials aren’t glamorous, but they are the
meat and potatoes of effective treatments and perhaps ultimately a cure
for Huntington’s disease. The gene-silencing approach like the Isis-Roche
initiative reported here August 23 has great promise.
In a two-hour interview with me at company headquarters in Carlsbad,
CA, on August 22, Isis Pharmaceuticals, Inc., officials and researchers
provided details about the Phase I trial of the antisense oligonucleotide
(ASO) ISIS-HTTRx. Isis and Roche, the Swiss drug maker, plan to start the
trial in Canada and Europe by mid-2015. If successful, the trial could result
in a drug in five or six years, by 2021.
By attacking the disease near its genetic roots, ISIS-HTTRx could
potentially reduce, partly reverse, and even prevent the symptoms of
Huntington’s. If it works as intended, this synthetic strand of DNA will
turn off the huntingtin gene messenger RNA that contains the instructions
to make the huntingtin protein in brain cells.
The huntingtin gene is essential for development very early in life, but
some people inherit it with an expanded length, leading to the production
of faulty huntingtin messenger RNA and huntingtin protein. Carriers of
genes expanded beyond a certain length develop Huntington’s disease. The
most recent evidence suggests that not only the faulty protein, but also the
faulty messenger RNA damages the brain.
ISIS-HTTRx will later receive a generic scientific name and, if marketed, a
trade name from Roche. HTT stands for huntingtin, and Rx for medical
treatment. Founded in 1989, Isis based its name on the Egyptian goddess
known for her healing powers.
“We have a drug that is going forward into clinical development,” said
Frank Bennett, Ph.D., Isis’s senior vice president for research, who has led
the development of the HD project. “Assuming all goes well, our plan is to
start clinical trials towards the first half of next year…. We’re very
enthusiastic about the drug.”
Dr. Bennett said that Isis is currently conducting standard toxicology
studies of the drug primarily in non-human primates, but also in rodents,
to assure that it will not cause harm to humans. A Phase I trial tests
primarily for safety and tolerability.
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Dr. Frank Bennett (photo by Dr. Ed Wild)
If the toxicology studies are successful, in the first quarter of 2015 Isis and
Roche will request formal authorization to start the Phase I trial from the
Canadian and European country equivalents of the U.S. Food and Drug
Administration (FDA).
Asked about previous delays in the clinical trial timeline and the certainty
of a 2015 start, Dr. Bennett affirmed that “we’re on track.”
“What’s really different is that we now have the drug,” he said. “The rest of
this is really kind of operational where we have to do additional important
work, but it’s not the necessarily the same kind of research we were doing
before, where there were a lot of unknowns that impacted timelines. We
have to do some experiments, but we … have a lot of experience doing
these toxicology studies. We aren’t anticipating any major issues
associated with them.”
“It’s never been more close,” said Douglas Macdonald, Ph.D., a long-time
contributor to the project. The director of drug discovery and development
for CHDI Management, Inc., which carries out the day-to-day mission of
the non-profit, HD drug-discovery biotech CHDI Foundation, Inc., Dr.
Macdonald was its point man during the foundation’s collaboration with
Isis from 2007-2013 and, along with others from CHDI, continues to
advise on the project.
With a $30 million investment in Isis’s preparations for the clinical trial
and the prospect of additional future payments, Roche last year acquired
the rights to the drug. The deal allowed CHDI to switch to an advisory role
as intended and enabled Roche to bring to bear its expertise in developing
drugs and bringing them to the market. Because of the high cost of drug
development, a small biotech firm such as Isis must partner with a drug
manufacturer to get its remedies to patients.
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Gene Veritas (aka Kenneth Serbin) at Isis headquarters in Carlsbad, CA
(photo by Alex Chambers, Isis intern)
Safety and tolerability
The trial of ISIS-HTTRx will involve approximately 36 early-stage
Huntington’s patients at four to six clinical trial sites (institutions, clinics,
and/or hospitals) in Canada and Europe, said Roger Lane, M.D., M.P.H.,
Isis vice president of clinical development and neurology and the
company’s lead organizer of the HD trial. Isis will announce the sites next
year after contract signings and approval from regulators. Isis and Roche
are focusing on sites with considerable experience in clinical trials in
Huntington’s disease.
Dr. Lane joined Isis in January 2014 in large part to help it ramp up the
ISIS-HTTRx trial.
He explained that the site clinical trial investigators will seek to recruit
individuals who have received a medical diagnosis of HD due to their high
level of motor symptoms (involuntary movements) but still in the early
stages of the illness. The trial will require people with a “very high level of
functioning” with Total Functional Capacity score of 11-13 (on a rising
scale of 1-13).
The patients need to be “fully capable of informed consent and able to
make a determination whether they want to be in the study or not,” he
said.
Although it’s widely recognized that cognitive loss and/or mood and
behavioral disorders can precede motor symptoms in HD, the ISIS-HTTRx
Phase I criteria will hone to the classic definition of motor onset, Dr. Lane
indicated. The patients without a lot of motor symptoms might qualify for
the eventual Phases II and III, depending on the observations made in
Phase I, he said.
Recruitment will take place through physicians, without public
advertisements. Patients will receive reimbursement for expenses
curehd.blogspot.com/2014/09/moving-toward-potential-treatment-isis.html
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associated with the trial.

Dr. Roger Lane (photo by Dr. Gene Hung, Isis)
“We want patients that are going to be fairly local to the site, so we don’t
want patients to come from a long way,” he explained. “If there’s any
complication, obviously we want them to be admitted very rapidly to the
clinical facility.”
Because a Phase I study focuses on safety and tolerability, patients will
receive one of four ascending doses of ISIS-HTTRx over three months.
Although ISIS-HTTRx might be able to reduce the amount of huntingtin
messenger RNA and protein as much as 90%, the highest dose is
anticipated to achieve a reduction of 50-70%, Dr. Lane explained.
The study will help determine the frequency and size of dosages for
eventual Phase II and Phase III trials. In line with the research done in
animals, a successful ISIS-HTTRx drug in humans might require dosage
only a few times per year, Dr. Lane said.
One in four patients will receive a placebo and therefore become a
comparison group, a standard practice in clinical trials to allow for a more
accurate understanding of the actual effect of a drug.
After the first dose, patients will undergo monitoring for at least 24 hours
before heading home.
Participants will undergo periodic neurological and neuropsychiatric
evaluation. The first evaluation will take place on the eve of the first dose.
After the last dose, researchers will continue to evaluate the patients for six
months. “We’ll be keeping a close eye on them,” Dr. Lane noted.
A spinal tap
Patients will receive the drug through a routine lumbar puncture, that is, a
needle inserted into the lower spine. Experienced neurologists will first
curehd.blogspot.com/2014/09/moving-toward-potential-treatment-isis.html
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withdraw a small amount of cerebral spinal fluid (CSF), to be analyzed as
part of the clinical trial research. (See more on this research below.)
Next, without withdrawing the needle, the doctors will inject a few
milliliters of a solution containing ISIS-HTTRx.
In technical terms, introducing the drug into the spinal canal is known as
an intrathecal injection. The CSF naturally travels to the brain. As in tests
with rodents and non-human primates, the ISIS-HTTRx should flow with
the CSF to the brain.
As Isis and Roche prepare for the trial, they will decide on the best position
for the patients – lying on their side or drooped over a chair, for instance –
to get as much of the drug as possible into the brain and minimizing
complications such as post-procedure headaches.
Dr. Lane explained that the doctors will use a so-called atraumatic needle,
which has a slightly more blunt point than other types of needles and
produces fewer post-procedural headaches.
In all, the actual procedure will last several minutes, with patients
spending no more than half an hour on this part of the trial, Dr. Lane said.
A local anesthetic can be used but is avoided by doctors because it can
cause swelling and make it harder to see under the skin, he added. Each
trial participant will undergo the procedure five times over the course of
the treatment period.
“I’ve had lumbar punctures myself, and I’ve given many lumbar punctures
to other people,” Dr. Lane continued. “If you’re in the hands of a very
experienced clinician who’s done them many times and who does not
impart any anxiety to the patient, then it’s not an inconvenient or painful
procedure. You feel a little bit of pressure perhaps in the back. If you do
not have any headache after the procedure, then it’s not really that
inconvenient. There is a psychological component to the thought of having
a needle put into your back. It’s not an agreeable thought to people. But it’s
not a painful procedure.”
Children undergoing spinal taps in an Isis clinical trial for a drug to treat
spinal muscular atrophy have not suffered any serious consequences, Dr.
Bennett pointed out.
For more on spinal taps and Huntington’s disease research, see Dr. Ed
Wild’s account of his own lumbar puncture by clicking here.
Isis and Roche are conducting joint research on the latter’s so-called brain
shuttle technology, which in the future might allow patients to take a drug
such as ISIS-HTTRx via an intravenous or subcutaneous (under the skin)
injection, Dr. Bennett said. The companies are not currently offering
public comment on that research, he added.
Timeline and study sites
Depending on the pace of recruitment, Phase I most likely will end in 2017,
Dr. Lane said. If Phase I is successful, Phase II could follow no sooner than
nine months later. All three phases of a clinical trial program typically take
at least five years.
With its large HD population and high-level medical facilities, why won’t
the U.S. host the Phase I trial?
“This trial is very small,” explained Dr. Lane. “So we only need a few sites.
We could have run the study in the U.S., but it didn’t make sense to run it
in both the U.S. and Europe. We chose Europe.”
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Dr. Lane said that the FDA’s clinical trial guidelines did not lead to the
decision to conduct the experiment abroad.
Aimed at demonstrating the efficacy of ISIS-HTTRx, Phase II would recruit
a much larger number of people and will certainly include the U.S., Dr.
Lane said.
Measuring the results
The trial investigators will check for the safety and tolerability of ISISHTTRx by putting the patients through several tests and measurements,
including clinical observations, behavioral and neuropsychiatric testing,
cognitive testing, a motor function examination, and neuroimaging
(putting the participants in a structural MRI machine and taking measures
of brain volume).
The measurements will also allow the researchers to make “assessments of
the disease itself,” Dr. Lane said.
“On the flip side, we can actually explore if we’re actually improving those
parameters [the patients’ condition],” he added.
However, Dr. Lane warned that the short duration of the study would limit
the use of such observations.
“We might not see much change, even if the drug was capable of inducing
change,” he said.
Key biomarkers: CSF and PET-ligands
A key set of observations on the disease will come from the CSF.
Researchers will also measure the ASO concentration in the fluid to
determine the amount of drug remaining in the brain.
They will also seek to identify and study biomarkers, that is, markers of the
disease and disease progression. Biomarkers can also indicate the effect of
a drug.
Because ISIS-HTTRx should reduce or “knock down” the huntingtin
messenger RNA and protein, the scientists want to measure and interpret
the amount of both normal and mutant huntingtin in the CSF. (Both types
exist in HD patients because they inherit a copy of the huntingtin gene
from each parent, one healthy, the other HD-affected.)
“There’s good news on that front in that we can measure huntingtin in the
CSF, but we don’t know yet what that means,” Dr. Lane explained. “Where
is it coming from? Is it coming from the blood? Is it coming from the
brain? If it’s coming from the brain, where in the brain is it coming from?”
(For a recent scientific discussion of mutant huntingtin in the CSF and
other bodily fluids, please click here.)
Isis and CHDI are collaborating to help answer these and other questions
about the CSF, said Holly Kordasiewicz, Ph.D., an Isis HD team member.
By studying rodents genetically modified to develop HD-like symptoms
and treated with ASOs, they aim to establish a correlation between the
amount of both normal and mutant huntingtin in the CSF and the brain.
That will help the researchers determine the frequency and quantity of the
drug’s dosage.
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Dr. Holly Kordasiewicz (photo by Dr. Gene Hung, Isis)
They are also gathering data on these questions from the above-mentioned
toxicology studies.
In addition to huntingtin protein, the researchers will observe other
markers in the CSF such as markers of neuronal damage, inflammation,
and transcriptional dysfunction (incorrect formation of proteins), Dr. Lane
added.
In collaboration with Dr. Macdonald and others at CHDI, the Isis HD team
is working to validate huntingtin lowering biomarkers. Beside the
development of assays (investigative procedures) to measure the
huntingtin protein in CSF, CHDI is also looking at PET-ligands to measure
the effects of ISIS-HTTRx in the brain. The ligand, sometimes called a PET
tracer, binds to a target or receptor in the brain, which can be measured in
people using PET scan imaging. The team has selected ligands to targets
that are altered in HD; the hope is that when huntingtin is lowered the
level of these targets will be restored, indicating that ISIS-HTTRx has a
desired effect.
Dr. Macdonald offered the example of dopamine receptors. “It is well
established that there is less of a receptor called the dopamine subtype 2
receptor in the brains of HD patients and animal models. This can be
measured using a specific PET tracer and we will look to see if that signal is
increased after huntingin-lowering with ISIS-HTTRx. If that occurs this
would be an indication that the drug is having the expected effect in the
brain.” The procedure is non-invasive, he added.
Dr. Lane said that the PET-ligand most likely will be ready only for Phase
II.
From these observations of the CSF and the PET-ligand signals, the
researchers hope to draw conclusions about the effectiveness of the drug, if
not in Phase I, certainly in Phases II and III.
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“Biomarkers are an important aspect of any drug development program,”
said Dr. Macdonald. “The fact that the Isis and Roche teams are seriously
looking at what biomarkers they can use in the clinic is a very positive
sign”.
Of course, the ultimate biomarker will be a healthy patient.

Dr. Douglas Macdonald (photo by Gene Veritas)
Completing the ‘missile’: ISIS-HTTRx
Isis’s choice of ISIS-HTTRx in the first quarter of this year came after seven
years of engineering and the testing of some 2,000 ASOs.
As Dr. Bennett put it in 2008, Isis technology is like a “laser-guided
missile” that targets a specific, disease-causing messenger RNA and
destroys it or takes it out of the body “so that you don’t produce that
messenger RNA.”
In 2012, Dr. Kordasiewicz, Dr. Bennett, and other researchers published
an article in the important journal Neuron demonstrating how the
experimental ASOs produced stunning improvement in the health of HDaffected mice.
Some researchers referred to the improvements in symptoms and signs
that persisted for a long time after the ASO treatment had finished
working in the affected animals as a “Huntington’s holiday.”
Throughout 2013 and into 2014, Isis has tweaked the drug formula, aiming
to improve safety and efficacy.
“It’s like you’re turning two different knobs, safety and efficacy, and
sometimes they go in different directions,” Dr. Bennett explained. “You
have to sort of adjust both knobs by screening a lot of different drugs that
ultimately give you what you’re hoping is the candidate.
“We’re very pleased that screening shows that it’s potentially a welltolerated drug. We wanted to make sure that it’s the most potent, most
efficacious and safest drug that we could identify. This candidate fits that
description.”
curehd.blogspot.com/2014/09/moving-toward-potential-treatment-isis.html
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Isis designed ISIS-HTTRx to knock down both the mutant form of the
huntingtin gene messenger RNA and the normal form. So far, research has
not shown any negative effects of knocking down the normal gene in
animals. Isis also has the technology to make mutant-gene messengerRNA-specific ASOs, that is, types that reduce only the bad huntingtin
protein.
“One of the big challenges for us was to decide whether we only inhibited
the mutant gene that expresses the expanded CAG repeat or we targeted
both the wild type [normal] as well as the mutant gene,” Dr. Bennett said.
“There are a lot of pros and cons for doing both. Ultimately we decided
that the technology with the mutant-specific compound wasn’t ready to
go.”
The HD team “felt it was important to get a drug into clinical trials as
quickly as we are comfortable with” in order to start evaluating the effects
on the disease of knocking down the huntingtin messenger RNA and
protein, he continued.
If ISIS-HTTRx works, the company may develop the mutant-specific ASOs
as second-generation drugs. As Dr. Bennett explained, this version would
require at least five different ASOs because of variations on the huntingtin
gene among individuals.
(You can learn more about mutant-specific ASOs by participating in a
Huntington’s Disease Society of America webinar 12-1 p.m. EDT on
September 24 with Amber Southwell, Ph.D., of the University of British
Columbia.)
The million-dollar question
At the close of the interview the Isis scientists assessed the clinical trial’s
potential impact on patients.
“That’s the million-dollar question,” said Dr. Kordasiewicz. “We’re all very
hopeful that it will work, but you just don’t know until you try it.”
“We’re going into the unknown territory now, because nobody’s really
developed a therapy to treat Huntington’s disease that’s really targeting
the huntingtin gene,” said Dr. Bennett. The hope is to stop disease
progression and potentially reverse some symptoms. “The science would
suggest we minimally could prevent the disease from progressing any
further.”
Dr. Lane said that ASO technology “has a lower likelihood of failing” than
traditional pharmaceutical products (so-called small molecules).
“With small molecules it’s not always clear exactly how they’re working,”
he explained. “The mechanism here [ASOs targeting the messenger RNA
of a specific gene] is so clear and so tied into the pathogenesis [cause] of
the disorder that there’s more chance at being successful.”
(Small molecule drugs make up 90 percent of the drugs currently on the
market. They are traditional, chemically manufactured drugs. Large
molecules, also called biologics, are a new class of drug that is becoming
increasingly important. They are proteins. ASOs represent another new
technology distinct from these other two classes of drugs.)
Dr. Lane added that even though HD has been well studied, not all of the
pathways of the disease – that is, the downstream biological processes
flowing from the mutant gene – have been described and understood.
Researchers still don’t “know for certain which are the important pathways
of the disease.”
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With ASOs, the downstream pathways are irrelevant, he said. “We go so
early in the pathway that we should help everything.”
Asymptomatic gene carriers cannot participate in the ISIS-HTTRx trial.
“Obviously this mechanism has great potential to be used in individuals
who have the mutant gene and are not yet symptomatic,” said Dr. Lane
said.

Members of the Isis team: (from left to right) Alex Chambers, intern;
Kristina Bowyer, director of communications and advocacy relations;
Dr. Roger Lane; Dr. Gene Hung; and Dr. Holly Kordasiewicz (photo by
Gene Veritas)
A transformation of medicine?
Isis has been making medical history.
In January 2013, the FDA approved Kynamro, a drug developed by Isis to
treat a rare type of extremely high cholesterol. It was the very first systemic
ASO drug to reach the market.
Shortly before that, Isis also made history with a clinical trial for an ASO
drug to treat amyotrophic lateral sclerosis (ALS). The program was paused
after Phase I because Isis is improving the drug for its ongoing
development program using the latest ASO technology.
“The ALS trial was the first time that anybody had put an oligonucleotide
drug into the intrathecal space [spinal cord], and so there were a lot of
safety concerns,” Dr. Bennett said. “The ALS experience showed that
intrathecal administration was very well tolerated.”
ISIS-HTTRx is an even more advanced ASO than the one used in the ALS
trial, he added.
A gene-silencing HD treatment would not only make history but could
transform medicine as the world prepares to care for tens of millions of
people affected by Alzheimer’s, Parkinson’s, dementia, and other
neurological conditions.
Said Gene Hung, Ph.D., a long-time member of the Isis HD team: “To date
I don’t think there are any disease-modifying drugs out there in CNS
[central nervous system] and neurodegenerative diseases, period.”
curehd.blogspot.com/2014/09/moving-toward-potential-treatment-isis.html
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ISIS-HTTRx could be the first. But it will take several years before progress
can be assessed.
See below links to previous reports on Isis.
"News flash: Isis and Roche hope to start Huntington's gene-silencing trial
in first half of 2015"
"A key new ally in the search for Huntington's disease treatments"
"Quickening the pace towards a Huntington's disease gene-silencing
clinical trial: pharma giant Roche, Isis enter partnership"
"Designing the best drug possible to defeat Huntington's disease"
"Building a 'laser-guided missile' to attack Huntington's disease"
"Observing the cure in progress"
Posted by Gene Veritas at 4:55 PM
Labels: antisense oligonucleotide , clinical trial , cure , disease , DNA , Frank
Bennett , gene silencing , HD gene carrier , huntingtin , Huntington's disease , Isis
Pharmaceuticals , Roche , symptoms , treatments

6 comments:
PDC said...
Hi Mr. Veritas. First and foremost I'd like to say thank you, for
doing all that you do to let the HD community as well as the
general public know what is going on in the fight for an HD
cure. I have just been diagnosed with HD. Searching for
answers I came across your blog. Reading some of the
information on your blog has given me hope and raised my
spirits. I thank you for that. If you don't mind me asking, how
long has it been since you first started showing symptoms?
12:01 PM, September 04, 2014

Gene Veritas said...
@ PDC. We are all in this together and will find the cure
together. I carry the mutated gene but, to my knowledge, not
yet shown any of the classic symptoms. I'm on Facebook and
Twitter @gene veritas if you want to connect there. Gene
2:14 PM, September 04, 2014

Anonymous said...
I sent you an e-mail at you dot-edu account, not specifically
related to this particular blog entry. Perhaps you could look for
it?
4:16 PM, September 05, 2014

PDC said...
Hey Gene, have you seen this?
http://www.raptorpharma.com/pipeline/rp103-drcysteamine-for-huntingtons-disease
curehd.blogspot.com/2014/09/moving-toward-potential-treatment-isis.html
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It looks like there may be some help coming around the corner.
Please check this out and let others know.
Thank you
11:43 AM, September 11, 2014

Anonymous said...
Just wanted to say thanks for this very thorough and careful
interview - your writing in this blog is truly a great service to
your fellow humans. I hope that this study has encouraging and
undelayed results.
2:03 PM, October 13, 2014

Wendy said...
You guys rock! I have hope for my family!!!
6:40 PM, April 08, 2015

Post a Comment

Newer Post

Home

Older Post

Subscribe to: Post Comments (Atom)

curehd.blogspot.com/2014/09/moving-toward-potential-treatment-isis.html

12/12

